A detailed history of New Edge Advisors, LLC transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 500 shares of BTAI stock, worth $165. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 500 -0.0%
Holding current value
$165
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$2.49 - $11.85 $3,735 - $17,775
-1,500 Reduced 75.0%
500 $1,000
Q2 2023

Aug 14, 2023

BUY
$6.39 - $28.58 $6,390 - $28,580
1,000 Added 100.0%
2,000 $13,000
Q1 2023

May 12, 2023

BUY
$17.7 - $33.24 $3,540 - $6,648
200 Added 25.0%
1,000 $18,000
Q4 2022

Feb 14, 2023

BUY
$10.25 - $22.43 $8,200 - $17,944
800 New
800 $17,000

Others Institutions Holding BTAI

About BioXcel Therapeutics, Inc.


  • Ticker BTAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,022,500
  • Market Cap $9.25M
  • Description
  • BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...
More about BTAI
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.